Videos

Dr. Christopher Flowers showcases a comprehensive and updated analysis of the ROSEWOOD study, evaluating the efficacy and safety of combining zanubrutinib with obinutuzumab versus obinutuzumab monotherapy.

Zanubrutinib plus Obinutuzumab versus Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma: Updated Analysis of the ROSEWOOD Study 

Christopher Flowers, MD, department chair, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses efforts to improve the frontline standard of care in diffuse large B-cell lymphoma (DLBCL).

The frontline standard of care therapy has not changed significantly over the past 20 years in DLBCL, Flowers says. In the early 2000s, it was observed that the addition of rituximab to standard CHOP (R-CHOP) therapy improved survival for elderly patients with DLBCL compared with CHOP alone, Flowers explains. 

Although several research efforts have attempted to improve upon frontline R-CHOP, no survival advantages have been demonstrated, Flowers says. For example, randomized phase 3 trials evaluating intensified treatment approaches, stem cell transplantation, and the addition of novel agents, including bortezomib (Velcade), lenalidomide (Revlimid), and ibrutinib (Imbruvica), have been reported without demonstrating improvement vs R-CHOP in most patients with DLBCL, Flowers concludes. 

Christopher Flowers, MD, discusses efforts to improve the frontline standard of care in diffuse large B-cell lymphoma.

 Dr. Flowers on Efforts to Improve Frontline Treatment in DLBCL

Christopher Flowers, MD, Department Chair, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the long-term efficacy with tafasitamab-cxix (Monjuvi) in combination with lenalidomide (Revlimid) in diffuse large B-cell lymphoma (DLBCL). 

Findings from the 3-year updated data of the phase 2 L-MIND trial (NCT02399085) demonstrated that at a median follow-up of at least 35 months, the median progression-free survival with tafasitamab/lenalidomide was 23.5 months for patients with relapsed/refractory DLBCL who received 1 prior treatment vs 7.6 months for patients who received 2 or more prior treatments, Flowers says. As such, there does appear to be a significant difference in efficacy based on number of prior treatments, Flowers adds. 

The median overall survival was 45.7 months in patients with 1 prior treatment vs 15.5 months in patients with at least 2 prior treatments, Flowers says. Although the trial was not powered to compared patients based on prior number of treatments, the efficacy data indicate that patients who had 1 prior therapy derived higher rates of complete responses vs those who received 2 or more prior therapies, Flowers, explains.

In many clinical scenarios, the less patients are pretreated, they better they tend to do with a novel treatment, Flowers explains. However, the differences observed based on prior treatment were notable with tafasitamab/lenalidomide, Flowers concludes.

Christopher Flowers, MD, discusses the long-term efficacy with tafasitamab-cxix in combination with lenalidomide in diffuse large B-cell lymphoma.  


Christopher Flowers, MD

Articles

Zanubrutinib plus Obinutuzumab versus Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma: Updated Analysis of the ROSEWOOD Study

Dr. Flowers on Efforts to Improve Frontline Treatment in DLBCL

Dr. Flowers on Long-Term Efficacy With Tafasitamab Plus Lenalidomide in DLBCL